CD28: A Potential Drug Target and Biomarker for Disease (G11197)
CD28: A Potential Drug Target and Biomarker for Disease
WIF1 (WIF1_HUMAN), also known as CD28, is a protein that is expressed in various tissues throughout the body, including the skin, hair, and nails. It is a member of the B-cell lymphocyte development molecule (BCR-1) family and is involved in the regulation of cell growth, differentiation, and survival.
WIF1 has been identified as a potential drug target and has been shown to play a role in the development and progression of various diseases, including cancer. Its functions and interactions with other molecules have led to its potential as a biomarker for disease diagnosis and treatment.
CD28 is a glycoprotein that consists of a transmembrane domain and a cytoplasmic tail. It is expressed in various tissues and is involved in the development and regulation of B cells, including the regulation of T cell responses.
WIF1 has been shown to play a role in the regulation of cell growth and differentiation. It has been shown to promote the growth and survival of various cell types, including T cells, B cells, and cancer cells.
WIF1 has also been shown to play a role in the regulation of cell survival. It has been shown to prevent the apoptosis (programmed cell death) of various cell types and to promote their survival.
WIF1 has been identified as a potential drug target due to its involvement in the regulation of cell growth, differentiation, and survival. Its functions and interactions with other molecules have led to its potential as a biomarker for disease diagnosis and treatment.
WIF1 has been shown to play a role in the development and progression of various diseases, including cancer. Its functions and interactions with other molecules have led to its potential as a biomarker for disease diagnosis and treatment.
For example, studies have shown that high levels of CD28 are associated with poor prognosis in individuals with various cancers, including breast, lung, and ovarian cancers. Additionally, studies have shown that inhibiting CD28 has been shown to improve the efficacy of chemotherapy in various cancers.
WIF1 has also been shown to play a role in the regulation of immune responses. It has been shown to regulate the activation and proliferation of T cells, which are important immune cells that play a role in the regulation of cancer.
In addition to its role in cancer, WIF1 has also been shown to play a role in the regulation of other diseases. For example, studies have shown that high levels of CD28 are associated with the development of autoimmune diseases, including rheumatoid arthritis and lupus. Additionally, studies have shown that inhibiting CD28 has been shown to improve the symptoms of neuroimmune diseases, such as multiple sclerosis and Alzheimer's disease.
WIF1 has also been shown to play a role in the regulation of inflammation. It has been shown to regulate the production and function of immune cells, including T cells and macrophages, which play a role in the regulation of inflammation.
In conclusion, WIF1 (WIF1_HUMAN) is a protein that is expressed in various tissues throughout the body and is involved in the regulation of cell growth, differentiation, and survival. Its functions and interactions with other molecules have led to its potential as a drug target and biomarker for disease diagnosis and treatment. Further research is needed to fully understand the role of WIF1 in the regulation of various diseases and to develop effective treatments.
Protein Name: WNT Inhibitory Factor 1
Functions: Binds to WNT proteins and inhibits their activities. May be involved in mesoderm segmentation
The "WIF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WIF1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6
